Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer

Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer

Abstract Background Although cisplatin-based chemotherapy has been used as the first-line treatment for ovarian cancer (OC), tumor cells develop resistance to cisplatin during treatment, causing poor prognosis in OC patients. Studies have demonstrated that overactivation of the phosphatidylinositol...

Full description

Bibliographic Details
Main Authors: Longxia Li, Di He, Qianqian Guo, Zhiyoung Zhang, Dan Ru, Liting Wang, Ke Gong, Fangfang Liu, Yourong Duan, He Li
Format: Article
Language:English
Published: BMC 2022-01-01
Series:Journal of Nanobiotechnology
Subjects:
Anticancer therapy
Cisplatin-resistant ovarian cancer
TP
miR497
PI3K/AKT/mTOR
Online Access:https://doi.org/10.1186/s12951-022-01264-5

Internet

https://doi.org/10.1186/s12951-022-01264-5

Similar Items